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Multiple sclerosis (MS), a common neurodegenera-
tive disease of the CNS, is characterized by the loss
of oligodendrocytes and demyelination. Tumor ne-
crosis factor a (TNF-a), a proinflammatory cytokine
implicated in MS, can activate necroptosis, a
necrotic cell death pathway regulated by RIPK1
and RIPK3 under caspase-8-deficient conditions.
Here, we demonstrate defective caspase-8 activa-
tion, as well as activation of RIPK1, RIPK3, and
MLKL, the hallmark mediators of necroptosis, in the
cortical lesions of human MS pathological samples.
Furthermore, we show that MS pathological samples
are characterized by an increased insoluble prote-
ome in common with other neurodegenerative dis-
eases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), and Huntington’s disease (HD). Finally,
we show that necroptosis mediates oligodendrocyte
degeneration induced by TNF-a and that inhibition of
RIPK1 protects against oligodendrocyte cell death in
two animal models of MS and in culture. Our findings
demonstrate that necroptosis is involved in MS
and suggest that targeting RIPK1 may represent a
therapeutic strategy for MS.
INTRODUCTION
Multiple sclerosis (MS) leads to focal inflammatory demyelination
in the brain and spinal cord white matter and to axonal degener-
ation. Although MS has been studied extensively (Buck and
Hemmer, 2011), the mechanism underlying oligodendrocyte
death is unclear. Preventing oligodendrocyte death may block
myelin loss and inhibit axonal degeneration, the major cause of
irreversible neurological disability in MS patients (Trapp and
Nave, 2008).
Tumor necrosis factor a (TNF-a), an important proinflamma-
tory cytokine, is elevated in active lesions and in the serum and1836 Cell Reports 10, 1836–1849, March 24, 2015 ª2015 The Authorcerebrospinal fluid (CSF) of MS patients and is correlated with
the severity of the lesions and MS disease progression (Sharief
and Hentges, 1991). TNF-a-induced oligodendrocyte death
resembles necrosis morphologically and without caspase acti-
vation (Jurewicz et al., 2005; Selmaj and Raine, 1988); however,
the mechanism by which this process occurs is unclear. RIPK1,
a death-domain-containing kinase, is a master mediator of
TNFR1 signaling upon activation by TNF-a (Ofengeim and
Yuan, 2013). Downstream of TNFR1, the activation of caspase-
8 is negatively regulated by the cellular FLICE-inhibitory protein
cFLIPL (Krueger et al., 2001). Caspase-8-regulated apoptosis
has an antagonistic relationship with RIPK1-regulated necropto-
sis; in the absence of caspase-8, the kinase activity of RIPK1
mediates necroptosis (Degterev et al., 2005; Holler et al., 2000;
Kaiser et al., 2011; Kawahara et al., 1998; Oberst et al., 2011;
Zhang et al., 2011a). Under apoptosis-deficient conditions,
RIPK1 interacts with RIPK3 to induce its phosphorylation and
form a RIPK1/RIPK3-containing complex, known as complex
IIb, which is critical for the induction of necroptosis (Cho et al.,
2009; He et al., 2009). Activated RIPK3, in turn, phosphorylates
MLKL, a pseudo-kinase, thereby inducing its oligomerization
and insertion into the plasma membrane, leading to the initiation
of necrosis (Cai et al., 2014; Sun et al., 2012; Wang et al., 2014).
Therefore, inhibition of RIPK1 kinase activity blocks necroptosis
induced by TNF-a by inhibiting its interaction with RIPK3 (Cho
et al., 2009). Since RIPK1 can be recruited to TNFR1, but not
TNFR2, inhibition of RIPK1 kinase activity offers a strategy to
selectively inhibit a subset of key deleterious signaling events
downstream of TNFR1.
In this article, we provide evidence for the defective activation
of caspase-8, as well as multiple hallmarks of necroptosis acti-
vation in human MS pathological specimens. Furthermore, we
identified an increase in proteins associated with the insoluble
proteome in MS patient samples—a significant portion of these
proteins were found in Lewy bodies from pathological brain
samples from patients with Parkinson’s disease (PD). Using
two animal models of MS, we show that inhibiting necroptosis
protects oligodendrocytes. Finally, we demonstrate that TNF-a
induces necroptosis of oligodendrocyte death in vitro. Our
data suggest that necroptosis is involved in the pathologys
associated with MS and that targeting necroptosis may provide
an oligodendrocyte protective strategy for therapeutic interven-
tion in this disease.
RESULTS
Dysregulation of the Cell Death Machinery in MS
Lesions
To explore the involvement of apoptosis and necroptosis in MS,
we characterized the activation profile of caspase-8. Unexpect-
edly, compared to that of age-matched controls, tissue samples
from cortical lesions of the MS patients showed a reduction
in the levels of active 18-kDa caspase-8 subunit and a corre-
sponding elevation in the levels of full-length and partially
processed p43-kDa caspase-8 subunit, the hallmarks of defec-
tive caspase-8 activation (Figure 1A; Table S1). Consistently,
caspase-8-specific activity was lower in tissue lysates from
the MS pathological brain samples when compared to that of
the control brains (Figure 1B). Since in the CNS, caspase-8 is
predominantly expressed in the microglial lineage, but not in
oligodendrocytes (Zhang et al., 2014), and because defects
in caspase-8 activation have been implicated in promoting
inflammation by engaging the necroptotic machinery (Wallach
et al., 2014), our data suggest that there might be a defect of
caspase-8 activity in microglia in MS cortical lesions that pro-
motes inflammation mediated by key mediators of necroptosis.
In contrast, we found that the expression of cFLIPL was signif-
icantly elevated in the MS samples (Figure 1C; Table S1). cFLIPL
is expressed inmany cell types includingmicroglia, oligodendro-
cyte precursor cells, and mature oligodendrocytes, but not neu-
rons, in the CNS (Zhang et al., 2014). Since cFLIPL is permissive
for the initial processing of pro-caspase-8 into the p43 subunit
but blocks the full activation of caspase-8 and the production
of p18 (Krueger et al., 2001), the elevated levels of cFLIPL sug-
gest a possible mechanism by which caspase-8 activation may
be inhibited in MS.
To examine the possible role of necroptosis in the pathogen-
esis of MS patients, we compared a microarray study of
MS patient samples (Mycko et al., 2004) on the upregulated
genes in chronic active lesions versus inactive lesions with the
hits from our small interfering RNA screen for regulators of
necroptosis (Hitomi et al., 2008). Interestingly, we found that
49% (20 of 41) of genes that were upregulated in chronic active
lesions were also identified as regulators of necroptosis (Table
S2). This analysis identified both positive and negative modu-
lators of necroptosis differentially regulated in the MS lesions,
suggesting that both degenerative and protective processes
are activated in MS, consistent with the double-edged sword
effect of TNF-a in this disease.
We characterized the expression and biochemical character-
istics of key mediators of necroptosis, including RIPK1, RIPK3,
and MLKL, in the brain tissues from control and MS patients.
We found that in tissue samples extracted with mild detergent
(Triton X-100/SDS), the levels of RIPK1 and RIPK3 proteins
were slightly increased in the MS samples (Figures S1A and
S1B; Table S1). Strikingly, the predominant portion of RIPK1
and RIPK3 in MS cortical lesions was extractable only by strong
detergent conditions (8M urea) (Figure 1D; 8 of 9MS for RIPK1; 9Cellof 11 MS for RIPK3). We next characterized the cells expressing
RIPK1 in lesions and peri-lesions from fixed MS samples by
immunostaining. We found that the expression of RIPK1 was
increased in the cortical lesions and identified a subset of cells
positive for both RIPK1 and CC1 or R461 (He et al., 2004),
markers for mature oligodendrocytes, as well as cells that
were positive for both RIPK1 and IBA1, a marker for microglia
(Figures 1E–1H; Figures S1C and S1D). Thus, both oligodendro-
cytes and microglia express RIPK1.
Phosphorylation of RIPK1 and RIPK3 has been recognized as
another set of hallmarks for the activation of necroptosis (Jouan-
Lanhouet et al., 2014). We characterized an antibody specifically
recognizing phospho-S14/15 of human and mouse RIPK1 (Fig-
ures S2A–S2D). In addition, an antibody against phospho-S166
of human RIPK1, a known RIPK1 autophosphorylation site (Deg-
terev et al., 2008), was developed as a marker for its activation
(Berger et al., 2014). We confirmed that S166 of RIPK1 was
phosphorylated upon the activation of necroptosis and that the
phosphorylation was inhibited by 7N-1 (Figures S2E and S2F).
Using these two phospho-RIPK1-specific antibodies, we found
that the increased levels of RIPK1 in the MS brain samples
were associated with an elevation of both S14/15 and S166
phosphorylation (Figures 1I and 1J). In addition, using an anti-
body against phospho-S227 of RIPK3, a marker for its activation
(Sun et al., 2012) (Figure S2F), we found that the phosphorylation
of RIPK3 was also markedly increased in the MS brain samples
compared to that of the control brains (Figure 1K). Activated
RIPK1 and RIPK3 interact to form complex IIb in necroptosis
(Cho et al., 2009; He et al., 2009); interestingly, we detected
the interaction of RIPK1 and RIPK3 in theMS, but not the control,
human samples (Figure 1L). Thus, RIPK1 and RIPK3, two key
mediators of necroptosis, are enriched in an activated state
and interact in the cortical lesions in MS patients.
To evaluate whether MLKL, a key executioner of necroptosis,
is also engaged inMS, we examined the phosphorylation of T358
in MLKL, a critical event mediated by RIPK3 that induces
the oligomerization and activation of MLKL in the execution of
necroptosis (Wang et al., 2014) (Figure S2F). While little reactivity
against anti-phospho-T358 was observed in the control tissues
(Figure S2G), robust reactivity for anti-phospho-T358 MLKL
was detected in the MS associated cortical lesions by both
immunostaining and western blot analysis (Figures 2A and 2B).
In addition, we found a substantially increased amount of
higher-molecular-weight phospho-MLKL in the MS pathological
samples, compared to that of control (Figure 2C). Since the
oligomerization of MLKL constitutes a key execution step for
necroptosis that leads to the disruption of the plasma
membrane (Cai et al., 2014; Chen et al., 2014; Dondelinger
et al., 2014; Jouan-Lanhouet et al., 2014; Wang et al., 2014),
we further characterized the state of MLKL in the control and
the MS brain samples using size-exclusion chromatography.
Interestingly, we found that while the majority of MLKL in control
tissues was eluted close to its predicted molecular weight
(55 kDa), the predominant peak ofMLKL in theMSpathological
samples was eluted as high-molecular-weight complexes above
250 kDa (Figure 2D), suggesting that MLKL is activated in MS.
Consistent with a CNS transcriptome study (Zhang et al.,







Figure 1. Dysregulation of the Apoptotic and Necroptotic Machinery in Cortical White Matter Lesions of MS Patients
(A) Western blotting analysis and quantifications of brain lysates from 11 control and 11 white matter lesions of MS cases probed with antibodies against
caspase-8 and b-actin. The quantification is shown as bar graphs to the right. Data are represented as the normalized means ± SEM; n = 11 replicates per group
(*p < 0.05, **p < 0.01, ***p < 0.001).
(B) The caspase-8-specific activity (a.u./mg of brain tissue) was assessed in cell lysates from control and MS tissue.
(C) Representative western blot analyses and quantifications of samples from 11 control and 11 white matter lesions of MS cases probed with antibodies against
c-FLIP and b-actin. The quantification is shown as bar graphs at the bottom. Data are presented as the normalized means ± SEM; n = 11 replicates per group
(*p < 0.05, **p < 0.01, ***p < 0.001).
(legend continued on next page)
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oligodendrocytes, but less in IBA1+ microglia (Figures 2E
and 2F; Figure S2H). Altogether, these data demonstrate the
biochemical characteristics of RIPK1, RIPK3, and MLKL acti-
vation in human MS pathological specimens and suggest an
active engagement of necroptosis in MS.
Protein Misfolding and Activation of RIPK3 in MS
Since proteins in the amyloid state, such as in b-amyloid plaques
associated with Alzheimer’s disease (AD), can typically only be
extracted by strong detergent/formic acid (Arai et al., 2006),
the enrichment of RIPK1 in the insoluble fractions of MS brain
suggests the possibility that RIPK1 might exist in an oligomeric
amyloid conformation. To directly test this possibility, we next
performed a rigorous sequential multi-step sarkosyl extraction
protocol (Arai et al., 2006), which was used to extract amyloid
plaques and neurofibrillary tangles in AD, to examine the
distribution of RIPK1 in brain tissues from control and MS
samples. While the majority of RIPK1 was easily extractable in
Tris-buffered saline buffer alone or gentle detergent in control
samples, a large fraction of RIPK1 could only be extracted
by strong detergents or formic acid in the cortical lesions of
MS patients (Figure 3A). These data suggest the possibility that
RIPK1 in MS exists in an amyloid-like conformation.
Since proteins in an oligomerized amyloid-like state are
known to have the capability to act as seeds to induce addi-
tional protein oligomerization (Holmes et al., 2014; Luk et al.,
2009; Spirig et al., 2014), we next examined a possible reorga-
nization of the total insoluble proteome in MS. We first used
A11, an antibody that can recognize amyloid proteins in
heterologous systems (Kayed et al., 2003, 2007; Shorter and
Lindquist, 2004), to perform immunostaining in sections of
cortical lesions from MS patients with anti-RIPK1. Interestingly,
we found that these lesions contained a significant number of
A11+ cells that were also positive for RIPK1 (Figure 3B). In
addition, we performed an unbiased quantitative proteomic
analysis of proteins enriched in MS pathological samples in
both the urea-soluble and formic-acid-soluble fractions by
mass spectrometry (Figure 3A). Using a dimethyl-isotope-label-
ing approach, we identified 141 proteins differentially enriched
in the formic-acid-soluble fraction and 552 proteins enriched
greater than 1.5-fold in the urea-soluble fraction of the MS pa-
tients tissue samples as compared to the control tissue in at
least one of the replicates (Table S3). Consistent with a general(D) Western blotting analysis of control and MS white matter lesion tissues for R
patients (left). The bar graphs on the right quantified western blotting data from 11
normalized to actin loading control. Data are presented as the normalized mean
(E) PLP and RIPK1 immunostaining of a large MS lesion within the cortical whi
reactivity for RIPK1 of all the tissues examined.
(F) Immunostaining using anti-RIPK1 and CC1 antibody, an oligodendrocyte ma
expression (lower panels).
(G) Immunostaining using anti-RIPK1 and IBA1 within the lesion (top panels); low
(H) Quantifications of RIPK1+ oligodendrocytes and microglia in normal white ma
Data are represented as the normalized means ± SEM; n = 4–6 images per grou
(I) A western blot of the urea soluble fraction from control and MS samples probe
(J) Awestern blot of the urea-soluble fraction from control andMS samples probed
(K) A western blot of the urea soluble fraction from control and MS samples probe
(L) The lysates from control and MS brain samples were immunoprecipitated with
against RIPK1 and RIPK3 (top); the input whole-cell lysates were probed with th
Celldemyelination in MS, we observed a reduction of myelin pro-
teins as assesses by mass spectrometry analysis (Figure S2I).
In addition, a targeted mass spectrometry analysis identified
RIPK1 and RIPK3 in MS, but not in control, samples. We
confirmed several hits identified in the proteomic analysis using
western blotting and demonstrated an enrichment of chap-
erone proteins and thioredoxin reductase as well as UCHL1,
a protein known to be involved in the pathogenesis of PD, in
the insoluble proteome of MS samples (Figure 3C).
Interestingly, a bioinformatic analysis of the proteins enriched
in the urea fraction of MS patients found that of the 418 unique
proteins identified in both urea fractions in duplicated mass
spectrometry runs, 138 proteins were also found in amass spec-
trometry dataset of 366 proteins (37.7% overlap) associated
with Lewy bodies (LBs) in PD, a classical example of inclusion/
amyloid in neurodegenerative disease (Figure 3D; Table S4).
The fold changes for the common hits between MS/control-
insoluble fraction dataset and LB/control-insoluble dataset
were plotted in a scatterplot (Figure 3E). The list of proteins
shared between the insoluble proteome of MS and LBs of PD
include proteins that are localized in the cytoplasmic, but not
nuclear, compartment and involved in multiple intracellular
processes including mediating protein and vesicular trafficking,
cytoskeletal organization, and macromolecular protein assem-
bly (data not shown). Furthermore, some of them (47 hits)
have been implicated in the pathogenesis of other neurodegen-
erative diseases including AD, PD, or Huntington’s disease (HD)
(Table S5). These data suggest the existence and possible
involvement of protein misfolding in the pathogenesis in MS.
We next examined the global phosphorylation pattern in the
insoluble proteome of control and MS samples for additional
evidence of the activation of RIPK3. Interestingly, we found
a significant increase in phosphorylation events with acidic res-
idues following the phosphorylation sites, consistent with the
consensus motif targeted by RIPK3 (Figure 3F; Table S6).
Thus, our data suggest that RIPK3 might be activated in MS,
which is in accordance with the enticing possibility that necrop-
tosis may mediate oligodendrocyte death in this disease.
Roles of RIPK1 and RIPK3 in Oligodendrocyte
Degeneration and Inflammation in Cuprizone Model
To assess whether RIPK1/RIPK3-dependent signaling is
involved in mediating oligodendrocyte degeneration in vivo, weIPK1 and RIPK3 levels in urea soluble fraction from three control and four MS
control and 11MS cases probed with antibodies against RIPK1 and RIPK3 and
s ± SEM; n = 11 replicates per group (**p < 0.01).
te matter from a patient with primary progressive MS, which showed strong
rker (upper panels). Higher-magnification images of a CC1+ cell with RIPK1
er panels show higher-magnification images highlighted in the white square.
tter (CTL) tissues and in MS lesions (MS) were shown as bar graphs to the right.
p replicates per group.
d with antibodies against phospho-RIPK1 serine 166, total RIPK1, and b-actin.
with antibodies against phospho-RIPK1 serine 14/15, total RIPK1, and b-actin.
d with antibodies against phospho-RIPK3 serine 227, total RIPK3, and b-actin.
antibody against RIPK3 followed by western blotting analysis with antibodies
e same antibodies, as well as b-actin.
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Figure 2. Activation of MLKL in Cortical
White Matter Lesions of MS Patients
(A) Phospho-MLKL immunostaining in the cortical
white matter lesion from a postmortem MS sample.
Higher-magnification images are shown below.
(B) A sequential solubility analysis of MLKL from a
control and a white matter lesion of a MS patient.
The fractions are Tris buffered saline soluble (TBS),
1% Triton soluble (TX), 2% SDS soluble (SDS), and
8 M urea soluble (Ur).
(C) A western blot of the whole-cell lysate (left) and
8 M urea-soluble fraction (right) from control and
MS samples probed with antibodies against phos-
pho-MLKL, total MLKL, and b-actin. The red box in
the urea fraction depicts higher-molecular-weight
phospho-MLKL+ bands found in the urea fraction
of MS samples.
(D) Brain lysates from three control individuals and
three MS patients were subjected to fractionation
using size exclusion column chromatography, and
the fractions were then analyzed by western blot-
ting using anti-MLKL.
(E and F) Immunostaining of MS cortical lesions
using anti-MLKL, CC1, and IBA1 antibodies (E).
A quantification of the cells that are positive for
both IBA1/MLKL and CC1/MLKL (F). Higher-
magnification images of IBA1+ cells that lack of
MLKL reactivity and CC1+ cells that show MLKL
reactivity (lower panels on both IBA1 and CC1
immunostaining).utilized the cuprizone model in which demyelination is mediated
by the cytotoxicity of cuprizone on oligodendrocytes (Blake-
more, 1972). We found that the motor deficits as well as marked
loss of myelin and CC1+ oligodendrocytes in the corpus
callosum and microglial activation induced were attenuated in
animals treated with 7N-1 (Figures 4A and 4B; Figures S3A
and S3B). Because a significant portion of oligodendrocyte
loss occurs in the third and fourth weeks following cuprizone
treatment without significant caspase activation (Arnett et al.,
2004; Buschmann et al., 2012; Matsushima and Morell, 2001),
we tested whether inhibiting RIPK1 can also preserve motor
function in a therapeutic mode of treatment. Within this context,
we found that delayed delivery of 7N-1 after dosing with cupri-
zone for 3 weeks still conferred a protective effect against motor
dysfunction (Figure S3C).
Consistent with the involvement of RIPK1, the number of
RIPK1+ cells in the corpus callosum in cuprizone-treated1840 Cell Reports 10, 1836–1849, March 24, 2015 ª2015 The Authorswild-type mice was significantly in-
creased. The RIPK1 expressing cells
include oligodendrocytes (CC1+, NG2+,
or Oligo2+), microglia (IBA1+), and astro-
cytes (GFAP+) (Figure 4C; Figure S3D).
Furthermore, we found that the levels
of RIPK1 protein were increased in the
corpus callosum of mice treated with
cuprizone in a time-dependent manner,
which was inhibited by 7N-1 (Figure 4D).
Cuprizone treatment also led to increased
phosphorylation of S14/15 RIPK1, whichwas inhibited by 7N-1 (Figure 4E). To further characterize
the formation of RIPK1 complexes after cuprizone treatment,
we immunostained sections of corpus callosum from cupri-
zone-treated animals with an anti-RIPK1 antibody and thioflavin
S (ThioS), a dye that binds to b sheet-rich structures and is
commonly used to visualize the formation of amyloid-contain-
ing structures (Sa´nchez et al., 2003). We found that cuprizone
treatment led to an increase of ThioS positivity throughout the
corpus callosum (Figure S3E). RIPK1+ cells that were also
positive for ThioS staining could be seen in cuprizone-treated,
but not control, animals (Figure 4F). To examine the presence
of oligomeric amyloid-containing structures, we used A11 to
immunostain sections containing the corpus callosum from
control and cuprizone-treated animals. We found that cupri-
zone treatment led to an enhancement of A11+ inclusions
throughout the corpus callosum, which included RIPK1+ cells




Figure 3. An Increase in Insoluble Proteomes
in MS
(A) A sequential solubility analysis of RIPK1 in brain
lysates from three control individuals and three
MS patients. The fractions are Tris buffered
saline soluble (TBS), 1% Triton soluble (TX), 1%
sarkosyl soluble (Sark), 8 M urea soluble (U1), 2%
SDS soluble (U2), and 70% formic acid soluble
(Form). Full-length RIPK1 is 75 kDa. Combined
samples from three MS patients and three control
individuals extracted with 8 M urea were used for
quantitative mass spectrometry analysis.
(B) Immunostaining using anti-A11, RIPK1, and PLP
at the lesion edge (top panels); lower panels show
higher-magnification images highlighted in the
white square.
(C) Western blotting analysis of the crude insoluble
fraction from control and MS samples used to
confirm the quantitative data obtained using mass
spectrometry; the data in the bar graph is the
average fold of enrichment of proteins identified by
proteomic analysis in 8 M urea fractions in MS
versus control samples.
(D and E) Proteins enriched at least 1.5-fold in
the urea fraction of MS samples in common with
the proteins associated with Lewy body in PD. The
percentage of overlap (D) and a scatter plot of the
common hits betweenMS and Lewy body in PD (E).
(F) Consensus of proteins phosphorylated in MS
is similar to the consensus of RIP3K substrates.
Phosphopeptides increased by >1.5-fold in the
MS urea fraction compared to the control urea
fractionwere analyzedbyWebLogosoftware (http://
weblogo.berkeley.edu/) to generate the consensus
graph of urea soluble phosphoproteome. RIPK3
substrate consensus was obtained from Phos-
phoNetworks (http://www.phosphonetworks.org/).that cuprizone treatment may lead to a generalized cellular
or intracellular reorganization that contain amyloid protein
structures, which can mediate the activation of RIPK1 and
RIPK3 by promoting their association.
To examine the role of RIPK3 in oligodendrocyte cell death
in vivo, we tested the susceptibility of RIPK3/ mice (Newton
et al., 2004) to cuprizone-mediated toxicity. Interestingly,
RIPK3/ mice showed increased resistance to cuprizone
induced-demyelination and a reduced number of IBA1+ micro-
glia and GFAP+ astrocytes and an improvement in motor
function compared to that of wild-type mice (Figures 5A–5C).
Consistently, we also observed a protection of the normal ultra-
structural features in the corpus callosum of cuprizone-treated
RIPK3/ mice including more myelinated axons with a better
g-ratio than that of wild-type mice treated with cuprizone (Fig-
ure 5D). Furthermore, the induction of RIPK1 and translocation
of RIPK1 into the insoluble fraction was significantly reduced
in RIPK3/ mice (Figure S3H). Since both inhibition of RIPK1
kinase by 7N-1 and RIPK3 deficiency can block demyelination,Cell Reports 10, 1836–1849motor dysfunction, and microglial activa-
tion mediated by cuprizone, we conclude
that RIPK1-RIPK3-dependent necropto-sis contributes to oligodendrocyte degeneration and inflam-
mation in vivo.
RIPK1 Kinase Inhibitor Attenuates EAE-Induced
Inflammation and Oligodendrocyte Degeneration
Experimental autoimmune/allergic encephalomyelitis (EAE)
models an inflammatory autoimmune demyelinating disease
in which demyelination is induced by subcutaneous injection of
synthetic peptides derived from myelin proteins. In this model,
the activation of TNFR1 by TNF-a is known to play an important
role in mediating the degeneration of oligodendrocytes in the
EAE model (Eugster et al., 1999). Surprisingly, we detected the
18-kDa active caspase-8 subunit in the spinal cord of control
samples (Figure 6A). Strikingly, after induction of EAE, the spinal
cord levels of full-length caspase-8 were significantly elevated,
but the presence of active 18-kDa caspase-8 subunit was corre-
spondingly decreased (Figure 6A). Interestingly, the levels of
c-FLIPL were also increased by EAE (Figure 6B). Thus, the induc-
tion of EAE may activate a mechanism to induce caspase-8 but, March 24, 2015 ª2015 The Authors 1841
Figure 4. Inhibition of RIPK1 Kinase Protects Oligodendrocytes from Necroptosis Induced by Cuprizone In Vivo
(A) Mice were fed either control or 0.2% cuprizone containing diet with vehicle or 7N-1 and assessed for motor deficit with rotarod test in a double-blind manner.
The time until mice fell off the rotarod was measured. Data are means ± SEM; n = 10–18 per group (*p < 0.05).
(B) Representative images of sections from medial corpus callosum show the marked reduction of fluoromyelin fluorescence intensity following 5 weeks of
cuprizone treatment. The images were scored in a double-blind fashion and quantified for demyelination. Data are means ± SEM; n = 5–8 per group (*p < 0.05).
(C) Representative images of corpus callosum (CC) sections from control and cuprizone-treated animals were immunostained by anti-RIPK1 and CC1, a marker
for oligodendrocytes.
(D) Mice were fed either control or 0.2%-cuprizone-containing diet for the indicated times; the CC was microdissected, lysed, and sequentially separated as
Triton-soluble (1%), RIPA-soluble, and urea-soluble fractions and analyzed by western blot analysis using antibodies against RIPK1 and RIPK3 as indicated and
normalized to b-actin. The quantifications were shown as bar graphs below. Data are presented as the normalized means ± SEM; n = 5–8 replicates per group
(*p < 0.05, **p < 0.01, ***p < 0.001).
(legend continued on next page)
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suppress its activation. Consistent with the data described
above from the human MS samples, reduced activation of
caspase-8 in EAE may be involved in mediating an inflammatory
response.
The levels of RIPK1 were significantly and consistently
elevated after EAE induction (Figures 6C and 6D). Interestingly,
the increased levels of RIPK1 were found in IBA1+ microglia,
as well as in some oligodendrocytes (Figure S4A). Consistent
with activation of RIPK1, increased phospho-S14/15 RIPK1
was detected (Figure 6E). To understand whether RIPK1 kinase
activity contributed causally to the detrimental effects in EAE, we
examined the effect of 7N-1 on this model. Administration of
7N-1, immediately after immunization (day 0) or at day 6 after
MOG peptide immunization, was able to markedly reduce dis-
ease severity compared to vehicle alone as measured by a
standard EAE neuroscore, while 7N-1 given at day 10 after im-
munization partially reduced disease severity (Figure 6F). Dosing
with 7N-1 also protected the weight loss associated with the in-
duction of EAE (data not shown). The loss of myelin-associated
proteins, MAG and MBP, was also significantly attenuated by
7N-1 (Figure 6G). Consistent with the protection of myelin,
CD11b+ monocyte infiltration was attenuated in animals treated
with 7N-1 relative to the monocyte infiltration in vehicle-treated
animals (Figure 6H). Furthermore, the levels of RIPK1were corre-
spondingly reduced by 7N-1 (Figure 6I). Consistent with a reduc-
tion of inflammatory cells infiltration, the mRNA and protein
levels of TNF-a were also reduced (Figures 6J and 6K) as well
as the levels of interleukin-6 (IL-6) and interleukin-1b (IL-1b) (Fig-
ures S4B and S4C).
7N-1- and vehicle-administered animals, however, showed
no difference in the spleen enlargement induced by EAE (Fig-
ure S4D). The titers of MOG-peptide-directed antibody were
similar in the sera of vehicle and 7N-1 treated animals (Fig-
ure S4E). The percentages of B220+, CD11b+, and CD3+ in
the spleens were not significantly different with or without
7N-1 (Figure S4F). Furthermore, the immunologic responses of
splenocytes isolated from control and 7N-1-treated animals
to MOG peptide in vitro were not significantly different, as
measured by the rate of proliferation and IL-6 production (Fig-
ures S4G and S4H). We also examined whether 7N-1 could
alter inflammatory-mediated induction of adhesion molecules,
similar to the mechanism of action of other therapeutics for
MS (Griffith and Luster, 2013). Specifically, we examined TNF-
a-mediated VCAM-1 upregulation in epithelial cells (human
umbilical vein epithelial cells) and found that 7N-1 did not inter-
fere with this process (Figure S4I). Finally, we also tested
whether 7N-1 altered the immune infiltration into the CNS by
performing adoptive transfer of MOG-primed GFP splenocytes
and lymphocytes into naive animals. 7N-1 did not change
the number of GFP-positive cells in the CNS (Figures S4J and
S4K). Thus, the treatment of 7N-1 significantly reduces the
loss of myelin and inflammation without significantly affecting(E) RIPA soluble fractions from CC of mice after 2, 3, or 5 weeks of cuprizone die
anti-RIPK1 and anti-p-S14/15 RIPK1.
(F) Representative images of sections from medial CC show the increase of RIP
control-treated animals following 5 weeks of cuprizone treatment.
Cellthe immunologic response to MOG peptide. Taken together
these data indicate that RIPK1 plays a causal role in the patho-
physiology of EAE.
To examine the role of RIPK3 in EAE, we compared the
expression of RIPK3 with that of RIPK1 in demyelinated lesions
after the induction of EAE. Interestingly, while many of the
RIPK1-positive cells in the lesions were positive for IBA1 (Fig-
ure S4A)—a marker for activated microglia—only a subset of
RIPK1+ cells were also positive for RIPK3 (Figure S5A). The in-
crease in RIPK3 protein levels was also less compared to the
levels of RIPK1 (Figure S5B). Consistent with its expression
levels, RIPK3 deficiency provided a mildly attenuated response
to the motor dysfunction induced by EAE (Figure S5C). Similar
to 7N-1 treated animals, RIPK3 deficiency had no effect on
the levels of splenic B220+, CD11b+, and CD3+ cells when
compared to that of wild-type animals (Figure S5D). Thus, in
contrast to the lesions induced by cuprizone, elevated expres-
sion of RIPK1 and, to a lesser extent, RIPK3 in the EAE model
was largely restricted to microglia. Altogether, we conclude
that EAE models an inflammatory demyelination disease medi-
ated predominantly by infiltrating monocytes and activated
microglia where RIPK1 kinase plays an important role.
Activation of Necroptosis in Oligodendrocytes by TNF-a
RIPK1, RIPK3, and MLKL, the core components of necroptotic
machinery, are expressed in the oligodendrocytes (Figures S2H
and S6A), while the expression of caspase-8, a critical mediator
of death-receptor-mediated apoptosis, is very low in oligo-
dendrocytes (Zhang et al., 2014), which is consistent with the
reports about the inability of oligodendrocytes to undergo
apoptosis upon TNF-a stimulation (Jurewicz et al., 2005; Sel-
maj and Raine, 1988). To evaluate the role of necroptosis
in the degeneration of oligodendrocytes, we examined the
sensitivity of oligodendrocytes to TNF-a-mediated necroptosis.
While apoptosis of oligodendrocytes has been found to occur
during the development of the CNS (Butts et al., 2008),
the mechanisms that mediate injury-induced oligodendrocyte
degeneration in adult life are not clear. To explore the mecha-
nism of oligodendrocyte cell death mediated by TNF-a, we
characterized the morphological and biochemical features of
oligodendrocyte cell death treated with TNF-a. Consistent
with previous reports (Jurewicz et al., 2005; Selmaj and
Raine, 1988), TNF-a treatment induced ultrastructural changes
reminiscent of necrosis in oligodendrocytes and without signif-
icant activation of caspase-3 (Figure 7A; Figures S6B and S6C).
Using time-lapse microscopy, we found that TNF-a-induced
oligodendrocyte cell death is characterized by rapid cyto-
plasmic membrane expansion, but without the accompanied
membrane blebbing characteristic of apoptosis (Figure S6D;
Movie S1) and similar to the morphological changes reported
for necroptotic cells (Degterev et al., 2005). Supporting the acti-
vation of necroptosis, the death of oligodendrocytes inducedt or 5 weeks of cuprizone diet with 7N-1 were analyzed by western blotting for
K1 reactivity and ThioS staining in cuprizone-treated animals as compared to
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Figure 5. RIPK3 Deficiency Protects against Demyelination in the Corpus Callosum after Cuprizone Treatment
(A) Wild-type or RIPK3/ mice were fed a normal diet with or without 0.2% cuprizone for 5 weeks to induce demyelination. Coronal sections were stained for
myelin with fluoromyelin at rostral, medial, and caudal parts of the CC, as indicated to the right of the images with a diagram from the Mouse Brain Library. The
images were scored in a double-blind fashion and quantified for demyelination. Data are means ± SEM; n = 11–14 per group.
(B) Coronal sections were stained with antibodies against the microglial marker IBA1 and the astrocyte marker GFAP. The amount of IBA1- and GFAP-positive
cells/100 mm2 in the CC was quantified. Data are means ± SEM; n = 5–6 per group.
(legend continued on next page)
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by TNF-a was inhibited by 7N-1 (Figures 7B and 7C). The pro-
tection of O1+ oliogdendrocytes by 7N-1 was further confirmed
using a high-content imaging-based approach (Figure 7D).
Finally, RIPK3 deficiency also protected oligodendrocytes
from TNF-a-mediated necroptosis (Figure 7E). Taken together,
these results suggest that necroptosis mediates oligodendro-
cyte cell death induced by TNF-a.
DISCUSSION
In this study, we provide substantial evidence for the activation
of the necroptotic machinery in MS, including the oligomeriza-
tion/aggregation and phosphorylation of RIPK1, RIPK3, and
MLKL in postmortem brain tissues from MS patients. Engage-
ment of the necroptotic machinery in oligodendrocytes, which
express RIPK1, RIPK3, and MLKL but are largely devoid of
caspase-8 expression, leads to necrosis. Importantly, we
discover a defective caspase-8 activation in MS cortical lesions.
Since caspase-8 is critical for suppressing the activation of
necroptosis, these data suggest that defective activation of
caspase-8 might be involved in the pathogenesis of MS. Thus,
similar to the requirement of caspase-8 for supporting normal
embryonic development (Kaiser et al., 2011; Oberst et al.,
2011; Zhang et al., 2011b), caspase-8 activity may be required
to maintain normal CNS function in adult life by suppressing
the activation of RIPK1 and RIPK3.
Since caspase-8 is predominantly expressed in microglia,
but not in oligodendrocytes, the elevated levels of inactive
caspase-8 as found in MS and EAE are most likely the result
of an activated inflammatory responses in microglia. On the
other hand, MLKL, a key executioner of necroptosis, is not
significantly expressed in microglia (Zhang et al., 2014) (Fig-
ure S5B), which may explain why microglia under normal con-
ditions do not die in response to caspase inhibition (Kim and Li,
2013). A defect in caspase-8 activation has been implicated in
promoting inflammation through the necroptotic machinery
(Wallach et al., 2014), which can be blocked by the RIPK1 in-
hibitor 7N-1 (Christofferson et al., 2012). Thus, the engagement
of the necroptotic machinery in microglia might promote inflam-
mation, which can be blocked by 7N-1. Since RIPK1 is more
highly expressed in activated microglia than RIPK3, targeting
RIPK1 may be appropriate to attenuate microglial-mediated in-
flammatory signaling.
Complex IIb, the critical signaling/executioner of necroptosis
formed by the interaction of RIPK1 and RIPK3, exists in an
amyloid-like conformation (Li et al., 2012). Consistent with the
activation of necroptosis in MS, we obtained multiple lines of
evidence for the formation of complex IIb in human MS sam-
ples. First, we detected the interaction of RIPK1 and RIPK3 in
MS, but not control, brain samples. Second, we found that a
significant portion of RIPK1 and RIPK3 in MS samples could
only be extracted by strong detergent or formic acid, which is(C) Mice were fed either control diet or 0.2%-cuprizone-containing diet with vehic
double-blind manner. The time until mice fell off the rotarod was measured. Data
(D) Ultrastructure of myelination in the CC was examined using electron microsc
cuprizone-treated groups are shown. Both the number ofmyelinated axons and th
per animals and 200 axons quantified. Data are means ± SEM (*p < 0.05).
Celltypical for proteins in an amyloid conformation. Third, we found
that MLKL existed in higher-order oligomers in MS, but not in
the control tissue. Fourth, we detected increased A11+ amyloid
immunostaining, a part of which overlapped with RIP1+ cells, in
MS samples. The consequences of forming the amyloid-like
containing complex IIb might not be limited to mediating nec-
roptosis per se, as the presence of protein amyloids may act
as seeds to induce the aggregation of additional proteins that
lead to changes in the overall proteome. Consistent with this
possibility, we identified an increase in proteins associated
with the insoluble proteome; a significant portion of these pro-
teins have previously been shown to be associated with LBs
in pathological brain samples from patients with PD. These
results suggest that the pathogenesis of MS may share a
component that is common with other neurodegenerative dis-
eases, such as AD, PD, or HD, where protein misfolding and
aggregation are known to play a crucial role in pathogenesis.
Similar to other neurodegenerative diseases, the formation
of amyloid-like proteins may underlie the progressive motor
dysfunction of MS, which is currently not addressed by existing
MS therapies that target the immunologic aspects of the
disease.
The two MS animal models used in this study each mimics
certain aspects of human MS. In the cuprizone model, ThioS+
and A11+ cells are significantly increased in the treated corpus
callosum; however, we did not detect robust changes in
caspase-8 activation or c-FLIP expression (data not shown).
The activation of RIPK1 and RIPK3 may be in part mediated
through this generalized effect of cuprizone in inducing protein
aggregation in the corpus callosum. Thus, the cuprizone model
might mimic aspects of protein aggregation in MS. On the
other hand, in the EAEmodel, we found an increased expression
of cFLIPL and a defective caspase-8 activation, similar to
what we found in the human MS brain samples, but no obvious
protein aggregation was found in EAE (data not shown). Since
caspase-8 is expressed by microglia, but not by oligodendro-
cytes, defective caspase-8 activation in EAE likely contributes
significantly to inflammation in a RIPK1-dependent manner.
Importantly, the two models share a common feature: RIPK1
is induced and phosphorylated. These results suggest that
targeting RIPK1 kinase may provide a strategy to selectively
inhibit the degenerative and inflammatory events mediated by
the necroptotic machinery in the CNS.
Our study implicates that elevated levels of c-FLIP might be
involved in suppressing the activation of caspase-8 in human
MS and in EAE. This finding may have significance in the etiology
of MS, since several members of the herpesvirus family, which
have been implicated in the etiology of MS (Virtanen and Jacob-
son, 2012), express v-FLIPs, the viral homologs of cellular FLIPs,
and can inhibit caspase-8 activation. Our data also suggest
the possibility that inhibition of caspase-8 by v-FLIPs might be
involved in promoting the onset of MS.le or 7N-1 administration and assessed for motor deficit on the rotarod test in a
are means ± SEM; n = 10–12 per group (*p < 0.05).
opy. Representative images from wilt-type and RIPK3/ in both control and
e g-ratio ofmyelinated axons are quantified. n = 2 animals per group; 30 images
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Figure 6. Caspase-8 Deficiency and RIPK1 Activation in EAE
(A and B) Western blotting analysis of control and EAE spinal cords (20 days post-immunization) for caspase-8 (A) and c-FLIPL (B). MBP and actin are used as a
loading control. The graphs below represent the quantification of western blot results of caspase-8 full-length and c-FLIPL in EAE spinal cords (15–20 days post-
immunization). Data are means ± SEM; n = 6–8 animals per group.
(C) Western blotting analysis of control and EAE spinal cord lysates for the expression of RIPK1 and bar graph quantification (below).
(D) Representative images of spinal cord sections immunostained with anti-RIPK1, anti-MBP (myelin basic protein), and DAPI to show low RIPK1 reactivity
in control untreated mice (CTL, upper panels) and increased RIPK1 immunostaining in the white matter after induction of EAE within an inflammatory lesion
(lower panels; 17 days post-immunization; 10–12 animals were used in each experimental group).
(legend continued on next page)
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Figure 7. Inhibition of RIPK1 Kinase and
RIPK3 Protects Oligodendrocytes from
Necroptosis Induced by TNF-a In Vitro
(A) Electron micrographs of control and TNF-a
(8 hr)-treated rat oligodendrocytes shows
non-apoptotic morphology of a dying oligoden-
drocyte. Images were taken at 2,9003 direct
magnification.
(B and C) Rat oligodendrocytes (8 days in vitro)
were treated with human (hTNF, 50 ng/ml) or
mouse (mTNF, 10 ng/ml) TNF-a (24–36 hr), and
viability was assessed by using the CellTiterGlo
assay (Promega). Representative images are
shown. Data are represented as the normalized
means ± SEM; n = 5–9 replicates per group
(*p < 0.05).
(D) Oligodendrocytes were plated in 96-well
plates and treated with increasing amounts
of mTNF-a (as indicated: T1 = 1 ng/ml; T10 =
10 ng/ml; T100 = 100 ng/ml) for 48 hr in the pres-
ence or absence of 7N-1. The cells were fixed and
stained with DAPI and O1-antigen specific anti-
body. High-throughput imaging and quantification
was used to count the number of cells in each
condition.
(E) Murine oligodendrocytes, isolated from either wild-type or RIPK3/mice, were treated with mTNFa (50 ng/ml, 24–36 hr). The cell viability was assessed using
CellTiterGlo assay. Data are presented as the normalized means ± SEM; n = 10–15 wells per group and repeated two to four times.EXPERIMENTAL PROCEDURES
Animals
C57BL/6 (B6) mice were purchased from the Jackson Laboratory. RIPK3/
mice were kindly provided by Vishiva Dixit of Genentech (Newton et al.,
2004). All animals weremaintained in a pathogen-free environment, and exper-
iments on mice were conducted according to the protocols approved by the
Harvard Medical School Animal Care Committee.
7N-1 Administration
7N-1 is orally available; however, its rodent in vivo t1/2 is only 1 hr.
To compensate for this short t1/2 of 7N-1, we developed a drinking water
formulation. We show that oral administration of 7N-1 in drinking water leads
to a constant plasma and CNS concentrations of 237 nM and 42 nM,
respectively (Figures S7A–S7D). Since the Kd of our third-generation opti-
mized 7N-1 for RIPK1 is 6 nM (Christofferson et al., 2012), the in vivo
concentration of 7N-1 through drinking water is sufficient for inhibiting
RIPK1. To ensure successful inhibition of RIPK1 kinase, we combined oral(E) Western blotting analysis of control and EAE (15–17 days post-immunization)
used as a loading control.
(F) Clinical scores (scored in double blind manner) of vehicle-treated (veh) and 7N
CFA as indicated. Data from three independent experiments are summarized as
assessed by both one-way ANOVA and t test).
(G) Western blotting analysis of spinal cord from either vehicle- or 7N-1-treated c
MAG (myelin associated glycoprotein), and anti-b-actin antibodies. Quantification
as ±SEM; n = 4–8 animals per group.
(H) Representative images and quantification of spinal cord lesions and immunos
(6 days after immunization) animals. The lesions were defined as five or more
quantification is represented in graphs as ±SEM; n = 5 animals per group; one o
(I) Western blotting analysis of spinal cords from either vehicle- or 7N-1-treated co
antibodies and quantified to that of b-actin as% of the control, vehicle-treated gro
group (*p < 0.05; **p < 0.01).
(J and K) The levels of TNF-amRNA (J) and protein (K) in the spinal cords of the c
RT-PCR and ELISA, respectively. The quantification is presented as mean ± SEM
Celladministration through drinking water supplemented with a single intraperito-
neal injection of 7N-1 on the first day of initiating treatment, which led to a
transient dose of 7N-1 in the blood and CNS at 500 mM and 100 mM,
respectively. No adverse effect was found to be associated with 7N-1 admin-
istration alone in this study and through a CRO contracted toxicology study
(data not shown). To prepare oral delivery of 7N-1, the compound (custom
synthesized) was first dissolved in DMSO (50% w/v) and then transferred
into 35% PEG solution, and this was suspended in water containing 2%
sucrose to increase the amount of daily water intake at a final concentration
of 0.5 mg/ml of 7N-1. Mice consumed 5–10 ml/day (2.5–5 mg/day). A similar
process (without sucrose) was used to dissolve 7N-1 for intraperitoneal
injection at concentration of (10 mg/kg). 7N-1 concentrations in plasma
and brain were determined by liquid chromatography-tandem mass spec-
trometry (Figure S7).
ELISA
Spinal cord was homogenized in 1% Triton X-100 in PBS supplemented with
Complete Protease Inhibitor (Roche). Total protein levels were determined byspinal cord lysates for anti-RIPK1 and anti-phospho-S14/15 RIPK1. b-Actin is
-1-treated animals starting day 0, 6, or 10 after immunization of MOG 35–55 in
the normalized mean ± SEM; n = 7–18 animals per group (*p < 0.05, **p < 0.01,
ontrol animals or vehicle 15–18 day post-induction of EAE with anti-MBP, anti-
of the levels of MAG and MBP normalized to b-actin is represented in graphs
taining with anti-MBP and anti-CD11b from control vehicle- and 7N-1-treated
CD11b+ cells within an area of 2502 mm in the spinal cord white matter. The
r two slices per animal from the same region of lumbar spinal cord (*p < 0.05).
ntrol animals, 15–18 day post-induction of EAEwith anti-RIPK1 and anti-b-actin
up ±SEM. The quantification was fromwestern blot data of n = 4–7 animals per
ontrol and treatment groups after 15–17 days of treatment were determined by
; n = 6–9 animals per group (**p < 0.01) in the graph.
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Bradford protein assay (Bio-Rad). The levels of TNF-a, IL-6, and IL-1b in the
spinal cord were determined using the appropriate ELISA kit according to
the manufacturer’s instructions (R&D Systems).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, six tables, and one movie and can be found with this article
online at http://dx.doi.org/10.1016/j.celrep.2015.02.051.ACKNOWLEDGMENTS
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